Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology

European Journal of Heart Failure

Volumn 14, Issue 3, 2012, Pages 268-277

  Broch, Kaspar ^a,b   Ueland, Thor ^a   Nymo, Ståle H ^a   Kjekshus, John ^a,b   Hulthe, Johannes ^c,d   Muntendam, Pieter ^e   McMurray, John J ^f   Wikstrand, John ^c   Cleland, John G ^g   Aukrust, Pål ^a,b   Gullestad, Lars ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d ASTRAZENECA R AND D   (Sweden)

^e BG Medicine Inc   (United States)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

^g UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Biomarkers; Heart failure; Prognosis; ST2

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; PROTEIN; ROSUVASTATIN; ST2 PROTEIN; UNCLASSIFIED DRUG;

AGED; ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART RATE; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK;

AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; HEART FAILURE; HUMANS; MALE; MYOCARDIAL ISCHEMIA; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECEPTORS, CELL SURFACE; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; STROKE VOLUME; TREATMENT FAILURE; VENTRICULAR FUNCTION, LEFT;

EID: 84857609914     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfs006     Document Type: Article

References (31)

1. Yousef ZR, Redwood SR, Marber MS. Postinfarction left ventricular remodelling: where are the theories and trials leading us? Heart 2000;83:76-80.
2. Shih H, Lee B, Lee RJ, Boyle AJ. The aging heart and post-infarction left ventricular remodeling. J Am Coll Cardiol 2011;57:9-17.
3. Fonarow GC. Epidemiology and risk stratification in acute heart failure. Am Heart J 2008;155:200-207.
4. Yndestad A, Damas JK, Oie E, Ueland T, Gullestad L, Aukrust P. Systemic inflammation in heart failure-the whys and wherefores. Heart Fail Rev 2006;11:83-92.
5. Petersen JW, Felker GM. Inflammatory biomarkers in heart failure. Congest Heart Fail 2006;12:324-328.
6. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005;23:479-490.
7. Januzzi JL Jr., Peacock WF, Maisel AS, Chae CU, Jesse RL, Baggish AL, O'Donoghue M, Sakhuja R, Chen AA, van Kimmenade RR, Lewandrowski KB, Lloyd-Jones DM, Wu AH. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 2007;50:607-613.
8. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ Heart Fail 2009;2:311-319.
9. Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Antman EM, Lee RT. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004;109:2186-2190.
10. Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, Rifai N, Cannon CP, Gerszten RE, Lee RT. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 2008;117:1936-1944.
11. Mueller T, Dieplinger B, Gegenhuber A, Poelz W, Pacher R, Haltmayer M. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem 2008;54:752-756.
12. Boisot S, Beede J, Isakson S, Chiu A, Clopton P, Januzzi J, Maisel AS, Fitzgerald RL. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail 2008;14:732-738.
13. Rehman SU, Mueller T, Januzzi JL Jr. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 2008;52:1458-1465.
14. Bayes-Genis A, Pascual-Figal D, Januzzi JL, Maisel A, Casas T, Valdes CM, Ordonez-Llanos J. Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure. Rev Esp Cardiol 2010;63:1171-1178.
15. Manzano-Fernandez S, Mueller T, Pascual-Figal D, Truong QA, Januzzi JL. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol 2011;107:259-267.
16. Pascual-Figal DA, Ordonez-Llanos J, Tornel PL, Vazquez R, Puig T, Valdes M, Cinca J, de Luna AB, Bayes-Genis A. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. J Am Coll Cardiol 2009;54:2174-2179.
17. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003;107:721-726.
18. Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P, Dries D, Tang WH, Wu AH, Fang JC, Boxer R, Sweitzer NK, Levy W, Goldberg L, Jessup M, Cappola TP. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 201; 4:180-187.
19. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Janosi A, Kamensky G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-2261.
20. Wedel H, McMurray JJ, Lindberg M, Wikstrand J, Cleland JG, Cornel JH, Dunselman P, Hjalmarson A, Kjekshus J, Komajda M, Kuusi T, Vanhaecke J, Waagstein F. Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur J Heart Fail 2009;11:281-291.
21. Dieplinger B, Januzzi JL Jr., Steinmair M, Gabriel C, Poelz W, Haltmayer M, Mueller T. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma-the Presage ST2 assay. Clin Chim Acta 2009;409:33-40.
22. Cleland JG, McMurray JJ, Kjekshus J, Cornel JH, Dunselman P, Fonseca C, Hjalmarson A, Korewicki J, Lindberg M, Ranjith N, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol 2009;54:1850-1859.
23. Pencina MJ, D'Agostino RB, Vasan RS. Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med 2010;48:1703-1711.
24. Pencina MJ, D'Agostino RB Sr., Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30:11-21.
25. McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, Lindberg M, Waagstein F, Grande P, Hradec J, Kamensky G, Korewicki J, Kuusi T, Mach F, Ranjith N, Wikstrand J. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation 2009;120:2188-2196.
26. Lohning M, Stroehmann A, Coyle AJ, Grogan JL, Lin S, Gutierrez-Ramos JC, Levinson D, Radbruch A, Kamradt T. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci USA 1998;95:6930-6935.
27. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008;7:827-840.
28. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007;117:1538-1549.
29. Weir RA, Miller AM, Murphy GE, Clements S, Steedman T, Connell JM, McInnes IB, Dargie HJ, McMurray JJ. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol 2010;55:243-250.
30. Kumar S, Tzimas MN, Griswold DE, Young PR. Expression of ST2, an interleukin-1 receptor homologue, is induced by proinflammatory stimuli. Biochem Biophys Res Commun 1997;235:474-478.
31. Pascual-Figal DA, Manzano-Fernandez S, Boronat M, Casas T, Garrido IP, Bonaque JC, Pastor-Perez F, Valdes M, Januzzi JL. Soluble ST2, high-sensitivity troponin T-and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail 2011;13:718-725.